Blood tests to monitor advanced lung cancer during care
Part of Cancer, Lungs & breathing clinical trials.
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18 years or older)
- Have advanced non-small-cell lung cancer (stage IIIB or IV) confirmed by tissue results
- Be able to have a liquid biopsy at the time specified for the group you’re in
- Have tumor biopsy testing done already (either at Centre Léon Bérard or with an outside pathology report available)
- Have health insurance coverage and sign consent
- Do the liquid biopsy before starting the treatment it applies to (chemo/immunotherapy timing matters)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a blood test (liquid biopsy) can help doctors better understand your lung cancer and plan your treatment. You'll have a blood sample taken alongside standard biopsies to see if the blood test provides useful information about your cancer.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study takes a small tumor sample early after starting targeted treatment (or uses blood if a biopsy isn’t possible) to look for clues—called biomarkers—about why some tumor cells survive. The results may help improve how future patients’ treatments are chosen for certain lung cancer gene mutations.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.